A New Way In: How Outside-the-box Science Sparked a Revolution in Targeting KRAS
At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize...
Tag: Pancreatic cancer
At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize...
During the third quarter of 2026, the U.S. Food and Drug Administration approved cancer treatments that expanded the options...
Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution,...
Cancer immunology expert and former AACR president Elizabeth Jaffee, MD, FAACR, discusses the latest progress in the research on...
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and...
The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting...
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic...
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and...